# Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer

> **NCT01219075** · NA · COMPLETED · sponsor: **University of Southern California** · enrollment: 110 (actual)

## Conditions studied

- BRCA1 Mutation Carrier
- BRCA2 Mutation Carrier
- Ductal Breast Carcinoma in Situ
- Lobular Breast Carcinoma in Situ
- Stage IA Breast Cancer
- Stage IB Breast Cancer
- Stage II Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer

## Interventions

- **DIETARY_SUPPLEMENT:** soy isoflavones
- **OTHER:** placebo
- **OTHER:** questionnaire administration
- **PROCEDURE:** magnetic resonance imaging
- **PROCEDURE:** biopsy
- **OTHER:** immunohistochemistry staining method
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** mammography

## Key facts

- **NCT ID:** NCT01219075
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-01
- **Primary completion:** 2022-11-24
- **Final completion:** 2022-11-24
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2023-11-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01219075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01219075, "Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01219075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*